Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aptose Biosciences Inc (APTOF)

Aptose Biosciences Inc (APTOF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC GlobeNewswire - Fri Dec 19, 4:05PM CST

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations GlobeNewswire - Sat Dec 6, 7:00AM CST

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical GlobeNewswire - Wed Nov 19, 12:22AM CST

SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Reports Third Quarter 2025 Results GlobeNewswire - Thu Nov 13, 4:00PM CST

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting GlobeNewswire - Mon Nov 3, 8:00AM CST

SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Shows Promising Results in AML Treatment Trial Tipranks - Fri Oct 17, 7:14AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptose Biosciences...

APTOF : 1.4500 (-3.97%)
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML GlobeNewswire - Thu Oct 16, 6:30AM CDT

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML GlobeNewswire - Mon Sep 22, 6:30AM CDT

SAN DIEGO and TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor GlobeNewswire - Fri Aug 22, 4:01PM CDT

SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial GlobeNewswire - Mon Aug 18, 6:30AM CDT

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates;...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)

Barchart Exclusives

Is AI Driving Silver Prices Higher? Barchart - Sun Dec 28, 12:28PM CST
Silver is a key component in high-tech electronics, an industry whose various components have combined to create and push AI forward. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot